Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Fineline Cube Aug 7, 2026
Company Deals

Biogen Completes $1 Billion Acquisition of RayThera to Bolster Immunology Portfolio with Novel Small-Molecule Pipeline

Fineline Cube Aug 7, 2026
Company Deals

Syndax Terminates Entinostat License Agreement with EOC HK, Ending Jingzhuda Commercial Rights in China

Fineline Cube Aug 6, 2026
Company Deals

AstraZeneca and CSPC Pharmaceutical Establish Joint Venture for Next-Generation Biologics Manufacturing Base in Shijiazhuang

Fineline Cube Aug 6, 2026
Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Policy / Regulatory

China’s CDE Releases 109th Reference Listed Drug Catalog, Adding 10 New Generic Drug Specifications

Fineline Cube Aug 6, 2026
Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Fineline Cube Aug 7, 2026
Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Fineline Cube Aug 7, 2026
Company Drug

Staidson’s STSP-0601 Receives Clinical Trial Approval for Hemophilia Treatment

Fineline Cube Sep 30, 2022

Staidson (Beijing) Pharmaceutical Co., Ltd (SHE: 300204), a China-based pharmaceutical company, has announced that it...

Company Drug

Henlius Biotech Gets FDA Nod for HLX07 Clinical Study in CSCC

Fineline Cube Sep 30, 2022

Shanghai Henlius Biotech (HKG: 2696) has announced that it has received approval from the US...

Company Deals

Suzhou Novoprotein Lists on Shanghai’s STAR Market for R&D Expansion

Fineline Cube Sep 30, 2022

Suzhou Novoprotein Scientific Co., Ltd, a China-based provider of protein technology and application solutions, has...

Company Medical Device

Rainmed Medical’s caFFR System Receives TGA Approval for Coronary Disease Diagnosis

Fineline Cube Sep 30, 2022

China-based Rainmed Medical Limited has announced that it has received market approval from Australia’s Therapeutic...

Company Deals

NeuShen Therapeutics Closes $20M Series Pre-A Financing for CNS Drug Development

Fineline Cube Sep 30, 2022

NeuShen Therapeutics has announced the successful closure of a $20 million Series pre-A financing round...

Company Drug

Zelgen Files NDA for Jacktinib to Treat Myelofibrosis in China

Fineline Cube Sep 29, 2022

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has filed a New...

Company

Innovent Biologics Reports 15.3% Revenue Growth in 2022 Interim Results

Fineline Cube Sep 29, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) has released its 2022 interim report, recording RMB 2.24...

Company Drug

Lepu Biotechnology’s MRG003 Receives Breakthrough Therapy Designation for Nasopharyngeal Carcinoma

Fineline Cube Sep 29, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received Breakthrough Therapy...

Company Drug

Lepu Biotechnology’s PD-1 Inhibitor HX008 Gains New Indication Approval

Fineline Cube Sep 29, 2022

China-based Lepu Biotechnology Co., Ltd (HKG: 2157) has announced that it has received another indication...

Company Drug

Neurophth Biotechnology Doses First Patient in Phase III Trial for NR082

Fineline Cube Sep 29, 2022

China-based gene therapy specialist Neurophth Biotechnology Ltd has announced that the first patient has been...

Company Drug

Bio-Thera Solutions Completes Phase I Study for COVID-19 Antibody BAT2022

Fineline Cube Sep 29, 2022

Guangzhou-based Bio-Thera Solutions (SHA: 688177) has announced the completion of all dosage groups (from 100...

Company

Allergan Aesthetics Opens Shanghai Innovation Center for Medical Aesthetics

Fineline Cube Sep 29, 2022

Allergan Aesthetics, a division of AbbVie, has officially opened its Shanghai innovation center, marking a...

Company

Biosyngen to Establish Cell Therapy GMP Facility in Singapore

Fineline Cube Sep 29, 2022

Biosyngen has announced plans to establish a Cell Therapy GMP Facility in Singapore, aimed at...

Company

Luye Pharma Reports Decline in H1 Revenue and Profits Amid Market Challenges

Fineline Cube Sep 29, 2022

China-based Luye Pharma Group (HKG: 2186) has released its 2022 interim report, recording RMB 2.85...

Company Medical Device

Parexel Opens Clinical Study Supply Chain Center in Suzhou

Fineline Cube Sep 29, 2022

US-based contract research organization (CRO) Parexel has announced the opening of its clinical study supply...

Company Drug

Abbisko Therapeutics Doses First Patient in Phase I Study of ABSK043

Fineline Cube Sep 29, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that the first patient has...

Company Drug

Arctic Vision Enrolls First Patient in Phase III Study for ARVN002

Fineline Cube Sep 29, 2022

China-based ophthalmology specialist Arctic Vision has announced the enrollment of the first patient in a...

Company Deals

3D Medicines Partners with Denfo Medical for Cancer Therapy Development

Fineline Cube Sep 29, 2022

China-based 3D Medicines has entered into a strategic partnership with compatriot firm Denfo Medical Group,...

Company Deals

Simcere Grants Almirall Global Rights to Autoimmune Drug SIM0278

Fineline Cube Sep 29, 2022

China’s Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has entered into a licensing agreement with...

Company Deals

Insight Lifetech Raises Funds for Cardiovascular Solutions Expansion

Fineline Cube Sep 29, 2022

Insight Lifetech Co., Ltd, a Shenzhen-based provider of cardiovascular precision intervention solutions, has reportedly secured...

Posts pagination

1 … 658 659 660 … 705

Recent updates

  • CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma
  • Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction
  • Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months
  • Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis
  • Westlake Consortium Secures NMPA Approval for Iscartrelvir, Novel Oral 3CLpro Inhibitor for Mild-to-Moderate COVID-19
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CARsgen Therapeutics Secures NMPA Clinical Trial Approval for Allogeneic CAR-T Therapy CT1190B in Relapsed/Refractory Large B-Cell Lymphoma

Company Deals

Transcenta and WuXi Biologics Forge Strategic CDMO Partnership with RMB 190 Million Manufacturing Facility Transaction

Company Drug

Takeda Expands Revestive Approval in China with New 1.25 mg Specification for Pediatric Short Bowel Syndrome Patients as Young as 4 Months

Company Drug

Hengrui Pharmaceuticals Secures Fifth NMPA Approval for Ivarmacitinib in Non-Radiographic Axial Spondyloarthritis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.